Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109850 · ClinicalTrials.gov registry record · Phase 2
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00109850 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 22 participants.
The verdict
NCT00109850, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of esophageal cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cetuximab together with combination chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with combination chemotherapy and radiation therapy works in treating patients with locally advanced esophageal cancer that cannot be removed by surgery.
Interventions
- DRUG cisplatin
- BIOLOGICAL cetuximab
- RADIATION radiation therapy
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2005-05 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109850
The ClinicalTrials.gov registry entry for NCT00109850 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00109850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109850 about?
NCT00109850 is a clinical study titled "S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer". RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of esophageal cancer by bl...
What is the current status of trial NCT00109850?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2005-05. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00109850?
The interventions under investigation include: cisplatin (DRUG), cetuximab (BIOLOGICAL), radiation therapy (RADIATION), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00109850?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.